- €137.15m
- €161.12m
- €50.93m
- 62
- 18
- 70
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.21 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.69 | ||
| EV to EBITDA | 14.07 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.64% | ||
| Return on Equity | 4.81% | ||
| Operating Margin | 10.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 33.59 | 37.64 | 39.72 | 46.01 | 50.93 | n/a | n/a | 8.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +288.44 | -60.78 | -14.47 | -94.09 | +104.23 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.
Directors
- Athanasios Lavidas CHM
- Tania-Panagiota Vranopoulou DCE
- Minas Tanes NVC (76)
- Dimitra Tsomokou CFO
- Spyridon Fotinos EVP
- Panagiotis Pavlou CAO
- Vasileios Vasilakopoulos CIO
- Katerina Tsardaka VBD
- Telemaque Lavidas DSL
- Amanda Christodoulopoulou OTH
- Katerina Frangioudaki OTH
- Panagiotis Kousoulis OTH
- Dimitrios Stringas OTH
- Venetsiana-Loukia Lavida NED
- Christos Diamantopoulos NID
- Dimitrios Gkertsos NID (56)
- Lito Ioannidou NID
- Odysseas Kyriakopoulos NID (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 23rd, 1975
- Public Since
- November 8th, 1995
- No. of Employees
- 189
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Athens Exchange- Shares in Issue
- 167,868,482
- Address
- Agias Marinas Street, Peania, ATHINA, 190 02
- Web
- https://www.lavipharm.com/
- Phone
- +30 2106691000
- Contact
- Vassilis Baloumis
- Auditors
- Grant Thornton
Upcoming Events for LAVI
FAQ
As of Today at 19:13 UTC, shares in Lavipharm SA are trading at €0.82. This share price information is delayed by 15 minutes.
Shares in Lavipharm SA last closed at €0.82 and the price had moved by +103.74% over the past 365 days. In terms of relative price strength the Lavipharm SA share price has outperformed the FTSE Global All Cap Index by +91.27% over the past year.
There is no consensus recommendation for this security.
Lavipharm SA does not currently pay a dividend.
Lavipharm SA does not currently pay a dividend.
Lavipharm SA does not currently pay a dividend.
To buy shares in Lavipharm SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.82, shares in Lavipharm SA had a market capitalisation of €137.15m.
Here are the trading details for Lavipharm SA:
- Country of listing: Greece
- Exchange: ATH
- Ticker Symbol: LAVI
Based on an overall assessment of its quality, value and momentum Lavipharm SA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lavipharm SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +17.27%.
As of the last closing price of €0.82, shares in Lavipharm SA were trading +7.65% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lavipharm SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lavipharm SA's management team is headed by:
- Athanasios Lavidas - CHM
- Tania-Panagiota Vranopoulou - DCE
- Minas Tanes - NVC
- Dimitra Tsomokou - CFO
- Spyridon Fotinos - EVP
- Panagiotis Pavlou - CAO
- Vasileios Vasilakopoulos - CIO
- Katerina Tsardaka - VBD
- Telemaque Lavidas - DSL
- Amanda Christodoulopoulou - OTH
- Katerina Frangioudaki - OTH
- Panagiotis Kousoulis - OTH
- Dimitrios Stringas - OTH
- Venetsiana-Loukia Lavida - NED
- Christos Diamantopoulos - NID
- Dimitrios Gkertsos - NID
- Lito Ioannidou - NID
- Odysseas Kyriakopoulos - NID